Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5651_Библиотеки_им_академика_М_И_Перельмана.pdf
Current Status of Commercial Anticancer Phytochemicals and Their Derivatives
Liao, X., & Leung, K. N. (2013). Tryptanthrin induces growth inhibition and neuronal differentiation in
the human neuroblastoma LA-N-1 cells. Chemico-Biological Interactions, 203(2), 512–521. doi:10.1016/j.
cbi.2013.03.001 PMID:23500671
Liao, X., Zhou, X., Mak, N. K., & Leung, K. N. (2013). Tryptanthrin inhibits angiogenesis by targeting
the VEGFR2-mediated ERK1/2 signalling pathway. PLoS One, 8(12), e82294. doi:10.1371/journal.
pone.0082294 PMID:24358167
Lichota, A., & Gwozdzinski, K. (2018). Anticancer activity of natural compounds from plant and marine
environment. International Journal of Molecular Sciences, 19(11), 3533. doi:10.3390/ijms19113533
PMID:30423952
Lin, J., Liu, X., Bao, Y., Hou, S., An, L., & Lin, X. (2008). Effects of isocamptothecin, a novel camptothecin analogue, on proliferation, apoptosis and telomerase activity in HaCaT cells. Experimental
Dermatology, 17(6), 530–536. doi:10.1111/j.1600-0625.2007.00674.x PMID:18218022
Lin, S. S., Lai, K. C., Hsu, S. C., Yang, J. S., Kuo, C. L., Lin, J. P., Ma, Y. S., Wu, C. C., & Chung, J.
G. (2009). Curcumin inhibits the migration and invasion of human A549 lung cancer cells through the
inhibition of matrix metalloproteinase-2 and-9 and Vascular Endothelial Growth Factor (VEGF). Cancer
Letters, 285(2), 127–133. doi:10.1016/j.canlet.2009.04.037 PMID:19477063
Lin, X., David, I. W., Huang, T., & Eugene, M. F. (1999). Experimental studies on topoisomerase inhibitor
camptothecin as an antipsoriatic agent. Chinese Medical Journal, 112(06), 504–508. PMID:11601327
Lin, Y. K., Chen, H. W., Yang, S. H., Leu, Y. L., Huang, Y. H., & Yen, H. C. (2012). Protective effect
of indigo naturalis extract against oxidative stress in cultured human keratinocytes. Journal of Ethno-
pharmacology, 139(3), 893–896. doi:10.1016/j.jep.2011.12.037 PMID:22212506
Liu, X., Lin, J., Bao, Y., Lin, X., & An, L. (2006). Camptothecin-mediated apoptosis and antiproliferation
effect is accompanied by down-regulation of telomerase activity in HaCaT cells. Journal of Dermato-
logical Science, 42(3), 262–264. doi:10.1016/j.jdermsci.2006.02.003 PMID:16574380
Livraghi, T., Solbiati, L., Meloni, M. F., Gazelle, G. S., Halpern, E. F., & Goldberg, S. N. (2003). Treatment of focal liver tumors with percutaneous radio-frequency ablation: Complications encountered in a
multicenter study. Radiology, 226(2), 441–451. doi:10.1148/radiol.2262012198 PMID:12563138
Magri, N. F., & Kingston, D. G. (1988). Modified taxols, 4. Synthesis and biological activity of taxols
modified in the side chain. Journal of Natural Products, 51(2), 298–306. doi:10.1021/np50056a017
PMID:2898009
Martel, J., Bueno, A., Dominguez, M. P., Llorens, P., Quirós, J., & Delgado, C. (2008). Percutaneous
radiofrequency ablation: Relationship between different probe types and procedure time on length and
extent of osteonecrosis in dog long bones. Skeletal Radiology, 37(2), 147–152. doi:10.100700256-007-
0416-1 PMID:18038230
Mathew, A. E., Mejillano, M. R., Nath, J. P., Himes, R. H., & Stella, V. J. (1992). Synthesis and evaluation
of some water-soluble prodrugs and derivatives of taxol with antitumor activity. Journal of Medicinal
Chemistry, 35(1), 145–151. doi:10.1021/jm00079a019 PMID:1346275
158
EBSCOhost - printed on 2/13/2023 11:18 AM via . All use subject to https://www.ebsco.com/terms-of-use
Current Status of Commercial Anticancer Phytochemicals and Their Derivatives
Mehta, N., Rao, P., & Saini, R. (2019). Evaluation of antioxidant and anticancer potential of Sesbania
aculeata-a multipurpose legume crop. Annals. Food Science and Technology (Valahia University of
Târgoviste), 20(1), 109–115.
Mehta, N., Rao, P., & Saini, R. (2021). Exploration of the antibacterial, antioxidant and anticancer potential of the seed coat extract of mungbean (Vigna radiata L. Wilczek). Plant Archives, 21(1), 1628–1633.
doi:10.51470/PLANTARCHIVES.2021.v21.no1.222
Moertel, C. G., Schutt, A. J., Reitemeier, R. J., & Hahn, R. G. (1972). Phase Il Study of Camptothecin
(NSC-100880) in the Treatment. Cancer Chemotherapy Reports. Part 1, 56(1), 95–101. PMID:5030811
Mousavi, S. H., Tavakkol-Afshari, J., Brook, A., & Jafari-Anarkooli, I. (2009). Role of caspases and Bax
protein in saffron-induced apoptosis in MCF-7 cells. Food and Chemical Toxicology, 47(8), 1909–1913.
doi:10.1016/j.fct.2009.05.017 PMID:19457443
Naasani, I., Seimiya, H., & Tsuruo, T. (1998). Telomerase inhibition, telomere shortening, and senescence of cancer cells by tea catechins. Biochemical and Biophysical Research Communications, 249(2),
391–396. doi:10.1006/bbrc.1998.9075 PMID:9712707
Nahar, L., & Sarker, S. D. (2019). Chemistry for pharmacy students: general, organic and natural prod-
uct chemistry. John Wiley & Sons.
Newman, D. J., & Cragg, G. M. (2020). Natural products as sources of new drugs over the nearly four
decades from 01/1981 to 09/2019. Journal of Natural Products, 83(3), 770–803. doi:10.1021/acs.
jnatprod.9b01285 PMID:32162523
Newman, D. J., Cragg, G. M., & Snader, K. M. (2000). The influence of natural products upon drug
discovery. Natural Product Reports, 17(3), 215–234. doi:10.1039/a902202c PMID:10888010
Newman, D. J., Cragg, G. M., & Snader, K. M. (2003). Natural products as sources of new drugs
over the period 1981− 2002. Journal of Natural Products, 66(7), 1022–1037. doi:10.1021/np030096l
PMID:12880330
Notte, A., Rebucci, M., Fransolet, M., Roegiers, E., Genin, M., Tellier, C., Watillon, K., Fattaccioli, A.,
Arnould, T., & Michiels, C. (2015). Taxol-induced unfolded protein response activation in breast cancer
cells exposed to hypoxia: ATF4 activation regulates autophagy and inhibits apoptosis. The International
Journal of Biochemistry & Cell Biology, 62, 1–14. doi:10.1016/j.biocel.2015.02.010 PMID:25724736
Noureini, S. K., & Wink, M. (2012). Antiproliferative effects of crocin in HepG2 cells by telomerase
inhibition and hTERT down-regulation. Asian Pacific Journal of Cancer Prevention, 13(5), 2305–2309.
doi:10.7314/APJCP.2012.13.5.2305 PMID:22901211
O’Dwyer, P. J., Leyland-Jones, B., Alonso, M. T., Marsoni, S., & Wittes, R. E. (1985). Etoposide (VP16–213) Current Status of an Active Anticancer Drug. The New England Journal of Medicine, 312(11),
692–700. doi:10.1056/NEJM198503143121106 PMID:2983208
EBSCOhost - printed on 2/13/2023 11:18 AM via . All use subject to https://www.ebsco.com/terms-of-use
159
Current Status of Commercial Anticancer Phytochemicals and Their Derivatives
Pathania, A. S., Kumar, S., Guru, S. K., Bhushan, S., Sharma, P. R., Aithagani, S. K., Singh, P. P., Vishwakarma, R. A., Kumar, A., & Malik, F. (2014). The synthetic tryptanthrin analogue suppresses STAT3
signaling and induces caspase dependent apoptosis via ERK up regulation in human leukemia HL-60
cells. PLoS One, 9(11), e110411. doi:10.1371/journal.pone.0110411 PMID:25383546
Paul, V. J. (Ed.). (1992). Ecological roles of marine natural products. Comstock Pub. Associates.
Pergola, C., Jazzar, B., Rossi, A., Northoff, H., Hamburger, M., Sautebin, L., & Werz, O. (2012). On
the inhibition of 5‐lipoxygenase product formation by tryptanthrin: Mechanistic studies and efficacy
in vivo. British Journal of Pharmacology, 165(3), 765–776. doi:10.1111/j.1476-5381.2011.01605.x
PMID:21797843
Piccart, M. J., Bertelsen, K., James, K., Cassidy, J., Mangioni, C., Simonsen, E., Stuart, G., Kaye, S.,
Vergote, I., Blom, R., & Pecorelli, S. (2000). Randomized intergroup trial of cisplatin–paclitaxel versus
cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results.
Journal of the National Cancer Institute, 92(9), 699–708. doi:10.1093/jnci/92.9.699 PMID:10793106
Powell, R. G., Weisleder, D. S. C. J., Smith, C. R. Jr, & Rohwedder, W. K. (1970). Structures of harringtonine, isoharringtonine and homoharringtonine [isolated from roots, stem, bark and seed of Cephalotaxus
harringtonia. Tetrahedron Letters, 11(11), 815–818. doi:10.1016/S0040-4039(01)97839-6 PMID:5436615
Priyadarshini, K., & Keerthi, A. U. (2012). Paclitaxel against cancer: A short review. Medicinal Chem-
istry (Shariqah, United Arab Emirates), 2(7), 139–141.
Rahier, N. J., Thomas, C. J., & Hecht, S. M. (2005). Camptothecin and its analogs. Anticancer Agents
from Natural Products, 5, 22.
Rayan, A., Raiyn, J., & Falah, M. (2017). Nature is the best source of anticancer drugs: Indexing natural
products for their anticancer bioactivity. PLoS One, 12(11), e0187925. doi:10.1371/journal.pone.0187925
PMID:29121120
Rowinsky, MD, E. K. (. (1997). The development and clinical utility of the taxane class of antimicrotubule
chemotherapy agents. Annual Review of Medicine, 48(1), 353–374. doi:10.1146/annurev.med.48.1.353
PMID:9046968
Sagar, S. M., Yance, D., & Wong, R. K. (2006). Natural health products that inhibit angiogenesis: A
potential source for investigational new agents to treat cancer—part 1. Current Oncology (Toronto, Ont.),
13(1), 14–26. doi:10.3747/co.v13i1.77 PMID:17576437
Seca, A. M., & Pinto, D. C. (2018). Plant secondary metabolites as anticancer agents: Successes in clinical
trials and therapeutic application. International Journal of Molecular Sciences, 19(1), 263. doi:10.3390/
ijms19010263 PMID:29337925
Senarisoy, M., Canturk, P., Zencir, S., Baran, Y., & Topcu, Z. (2013). Gossypol interferes with both type
I and type II topoisomerase activities without generating strand breaks. Cell Biochemistry and Biophys-
ics, 66(1), 199–204. doi:10.100712013-012-9468-5 PMID:23161103
160
EBSCOhost - printed on 2/13/2023 11:18 AM via . All use subject to https://www.ebsco.com/terms-of-use
Current Status of Commercial Anticancer Phytochemicals and Their Derivatives
Sgambato, A., Ardito, R., Faraglia, B., Boninsegna, A., Wolf, F. I., & Cittadini, A. (2001). Resveratrol,
a natural phenolic compound, inhibits cell proliferation and prevents oxidative DNA damage. Mutation
Research/Genetic Toxicology and Environmental Mutagenesis, 496(1-2), 171–180. doi:10.1016/S1383-
5718(01)00232-7 PMID:11551493
Shu, Y. Z. (1998). Recent natural products based drug development: A pharmaceutical industry perspective. Journal of Natural Products, 61(8), 1053–1071. doi:10.1021/np9800102 PMID:9722499
Sondhi, S. M., Rani, R., Singh, J., Roy, P., Agrawal, S. K., & Saxena, A. K. (2010). Solvent free synthesis,
anti-inflammatory and anticancer activity evaluation of tricyclic and tetracyclic benzimidazole derivatives. Bioorganic & Medicinal Chemistry Letters, 20(7), 2306–2310. doi:10.1016/j.bmcl.2010.01.147
PMID:20188544
Stähelin, H. F., & von Wartburg, A. (1991). The chemical and biological route from podophyllotoxin glucoside to etoposide: Ninth Cain memorial Award lecture. Cancer Research, 51(1), 5–15. PMID:1988106
Suzuki, K., Yahara, S., Hashimoto, F., & Uyeda, M. (2001). Inhibitory activities of (−)-epigallocatechin3-O-gallate against topoisomerases I and II. Biological & Pharmaceutical Bulletin, 24(9), 1088–1090.
doi:10.1248/bpb.24.1088 PMID:11558576
Takano, I., Yasuda, I., Nishijima, M., Hitotsuyanagi, Y., Takeya, K., & Itokawa, H. (1996a). Drupangtonine, a novel antileukemic alkaloid from Cephalotaxus harringtonia var. drupacea. Bioorganic &
Medicinal Chemistry Letters, 6(14), 1689–1690. doi:10.1016/0960-894X(96)00302-2
Takano, I., Yasuda, I., Nishijima, M., Hitotsuyanagi, Y., Takeya, K., & Itokawa, H. (1996b). Alkaloids
from Cephalotaxus harringtonia. Phytochemistry, 43(1), 299–303. doi:10.1016/0031-9422(96)00217-8
PMID:9041720
Takano, I., Yasuda, I., Nishijima, M., Hitotsuyanagi, Y., Takeya, K., & Itokawa, H. (1996c). New Cephalotaxus Alkaloids from Cephalotaxus harringtonia var. drupacea. Journal of Natural Products, 59(10),
965–967. doi:10.1021/np9604543
Takano, I., Yasuda, I., Nishijima, M., Hitotsuyanagi, Y., Takeya, K., & Itokawa, H. (1996d). Cephalotaxidine, a novel dimeric alkaloid from Cephalotaxus harringtonia var. drupacea. Tetrahedron Letters,
37(39), 7053–7054. doi:10.1016/0040-4039(96)01549-3
Takano, I., Yasuda, I., Nishijima, M., Hitotsuyanagi, Y., Takeya, K., & Itokawa, H. (1996e). New oxygenated Cephalotaxus alkaloids from Cephalotaxus harringtonia var. drupacea. Journal of Natural Products,
59(12), 1192–1195. doi:10.1021/np9605044
Takano, I., Yasuda, I., Nishijima, M., Yanagi, Y., Takeya, K., & Itokawa, H. (1997). Ester-type Cephalotaxus alkaloids from Cephalotaxus harringtonia var. drupacea. Phytochemistry, 44(4), 735–738.
doi:10.1016/S0031-9422(96)00574-2 PMID:9041720
Ueda, Y., Mikkilineni, A. B., Knipe, J. O., Rose, W. C., Casazza, A. M., & Vyas, D. M. (1993). Novel
water soluble phosphate prodrugs of Taxol® possessing in vivo antitumor activity. Bioorganic & Me-
dicinal Chemistry Letters, 3(8), 1761–1766. doi:10.1016/S0960-894X(00)80058-X
EBSCOhost - printed on 2/13/2023 11:18 AM via . All use subject to https://www.ebsco.com/terms-of-use
161
Current Status of Commercial Anticancer Phytochemicals and Their Derivatives
Ulukan, H., & Swaan, P. W. (2002). Camptothecins. Drugs, 62(14), 2039–2057. doi:10.2165/00003495-
200262140-00004 PMID:12269849
Usha, S., Johnson, I. M., & Malathi, R. (2005). Interaction of resveratrol and genistein with nucleic acids.
BMB Reports, 38(2), 198–205. doi:10.5483/BMBRep.2005.38.2.198 PMID:15826497
Wall, M. E., Wani, M. C., Cook, C. E., Palmer, K. H., McPhail, A. A., & Sim, G. A. (1966). Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor
inhibitor from Camptotheca acuminate. Journal of the American Chemical Society, 88(16), 3888–3890.
doi:10.1021/ja00968a057
Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P., & McPhail, A. T. (1971). Plant antitumor agents.
VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia.
Journal of the American Chemical Society, 93(9), 2325–2327. doi:10.1021/ja00738a045 PMID:5553076
Williams, D. H., Stone, M. J., Hauck, P. R., & Rahman, S. K. (1989). Why are secondary metabolites
(natural products) biosynthesized? Journal of Natural Products, 52(6), 1189–1208. doi:10.1021/
np50066a001 PMID:2693613
Xiao, K., Jiang, J., Guan, C., Dong, C., Wang, G., Bai, L., Sun, J., Hu, C., & Bai, C. (2013). Curcumin
induces autophagy via activating the AMPK signaling pathway in lung adenocarcinoma cells. Journal
of Pharmacological Sciences, 123(2), 102–109. doi:10.1254/jphs.13085FP PMID:24048094
Yamaguchi, T., Harada, N., Ozaki, K., Arakawa, H., Oda, K., Nakanishi, N., Tsujihara, K., & Hashiyama, T. (1999). Synthesis of taxoids 5. Synthesis and evaluation of novel water-soluble prodrugs of a
3¢-desphenyl-3¢-cyclopropyl analogue of docetaxel. Bioorganic & Medicinal Chemistry Letters, 9(12),
1639–1644. doi:10.1016/S0960-894X(99)00257-7 PMID:10397492
Yang, S., Li, X., Hu, F., Li, Y., Yang, Y., Yan, J., Kuang, C., & Yang, Q. (2013). Discovery of tryptanthrin
derivatives as potent inhibitors of indoleamine 2, 3-dioxygenase with therapeutic activity in Lewis lung
cancer (LLC) tumor-bearing mice. Journal of Medicinal Chemistry, 56(21), 8321–8331. doi:10.1021/
jm401195n PMID:24099220
Yokoyama, M., Noguchi, M., Nakao, Y., Pater, A., & Iwasaka, T. (2004). The tea polyphenol,(−)epigallocatechin gallate effects on growth, apoptosis, and telomerase activity in cervical cell lines.
Gynecologic Oncology, 92(1), 197–204. doi:10.1016/j.ygyno.2003.09.023 PMID:14751158
Yu, S. T., Chern, J. W., Chen, T. M., Chiu, Y. F., Chen, H. T., & Chen, Y. H. (2010). Cytotoxicity and
reversal of multidrug resistance by tryptanthrin-derived indoloquinazolines. Acta Pharmacologica Sinica,
31(2), 259–264. doi:10.1038/aps.2009.198 PMID:20139909
Zhao, Z., Kingston, D. G., & Crosswell, A. R. (1991). Modified taxols, 6. Preparation of water-soluble
prodrugs of taxol. Journal of Natural Products, 54(6), 1607–1611. doi:10.1021/np50078a018
Zhuang, W., Long, L., Zheng, B., Ji, W., Yang, N., Zhang, Q., & Liang, Z. (2012). Curcumin promotes
differentiation of glioma‐initiating cells by inducing autophagy. Cancer Science, 103(4), 684–690.
doi:10.1111/j.1349-7006.2011.02198.x PMID:22192169
162
EBSCOhost - printed on 2/13/2023 11:18 AM via . All use subject to https://www.ebsco.com/terms-of-use
Chapter 9
Medicinal Plants for the
Treatment of Type 2 Diabetes
Bui Thanh Tung
VNU University of Medicine and Pharmacy, Vietnam National University, Hanoi, Vietnam
Nguyen Thi Ngoc Huyen
VNU University of Medicine and Pharmacy, Vietnam National University, Hanoi, Vietnam
163
ABSTRACT
Type 2 diabetes (T2D) is a metabolic disorder related to persistent hyperglycemia. It is characterized by
lack of secretion and/or reduce activity of insulin, which causes many chronic complications. Medicinal
plants offer a passel of remedies that resolve symptomatology and mitigate the progression of T2D.
Although several pre-clinical and clinical investigations indicate the success of conventional medicine
in the prevention and treatment of diabetes, still there are several side effects. Consequently, this necessitates the exploration of complementary and alternative treatment programs that may include natural
products as safe and effective anti-diabetic candidates. This chapter reviews the medicinal plants and
their bioactive compounds utilized in diabetes therapy and molecular targets of Type 2 diabetes treatment. The authors elucidate present findings and contribute to ongoing investigations into potential
alternative therapies for T2D.
INTRODUCTION
Diabetes mellitus, a chronic state of metabolic diseases, is caused by deficiency of insulin secretion and
insulin activity. There are three primary types of the disease: Type 1 diabetes (T1D), Type 2 diabetes
(T2D) and Gestational diabetes (GD). Of the three, Type 2 diabetes or non-insulin dependent diabetes
(NIDDM) is the most prevalent form of this disorder in the world (Jin et al., 2019). The preponderance
of this pathology is projected to significantly increase from 285 million (9.3%) in 2019 to 578 million
(10.2%) in 2030 and 700 million (10.9%) in 2045 (Federation, 2019). Although the main risk factors for
T2D are obesity, age, family history, hypercaloric diets and inactive lifestyle, the effect of this disease on
non-obese and physically active people is fundamental in determining an onset mechanism (Ferhati et
DOI: 10.4018/978-1-6684-5129-8.ch009
Copyright © 2022, IGI Global. Copying or distributing in print or electronic forms without written permission of IGI Global is prohibited.
EBSCOhost - printed on 2/13/2023 11:18 AM via . All use subject to https://www.ebsco.com/terms-of-use
Medicinal Plants for the Treatment of Type 2 Diabetes
al., 2019). The stable levels of glucose are maintained by a complicated mechanism containing hepatic
glycogenolysis and gluconeogenesis. After a meal, pancreatic β-cells secrete insulin preventing hepatic
glucose output and stimulating the glucose absorption into peripheral tissues (Alvim et al., 2015). The
World Health Organization has suggested that the oral glucose tolerance test (OGTT) is designed for
the diagnostic criteria of diabetes with fasting glucose 7.0 mmol/L or more. In addition, the expert
committee of the American Diabetes Association recommended a cut-point for the diagnostic criteria
at 6.5% or more of HbA1c level (Forouhi & Wareham, 2010). The aim of these therapeutic options is
to maintain patient blood glucose levels close to physiological range and to prevent serious symptoms
as well as late complications in the long term. The antidiabetic therapy currently contains oral drugs
reducing hyperglycaemia and exogenous insulin injection as a last method (Ferhati et al., 2019). This
book chapter will focus on proposing or determining a mechanism of action for antidiabetic agents
employed in the treatment of T2D.
MOLECULAR MECHANISM OF TYPE 2 DIABETES TREATMENT
AMP-Activated Protein Kinase (AMPK)
The AMPK heterotrimeric complex contains α-catalytic subunit with β and γ-regulatory subunits. Twelve
different AMPK molecules are comprised of four isoforms of α and β subunits (α
isoforms of γ subunit (γ
, γ2, γ3) (Alvim et al., 2015). Recent studies show the important role of AMPK
1
, α2, β1,β2) and three
1
in glucose uptake with in muscle cells in T2D patients. After the skeletal muscles contract, the glucose
uptake is prompted by increasing AMP/ATP ratio and decreasing creatine/phosphocreatine ratio. The
levels of AMP increase significantly leading to AMPK activation via residual threonine phosphorylation
172
) in the α-subunit by LKBI (upstream serine-threonine kinase) (Alvim et al., 2015). Another study
(Thr
also reported that AMPK activated by metformin based on the interaction between AMPK, LKBI and
axin in liver in vivo, HEK (Human embryonic kidney)-293 cells and embryonic fibroblasts of mouse
(Carling, 2017). The 5- aminoimidazole-4-carboxamide-1-β-D-ribonucleoside (AICAR) activation is
similar to AMP affecting AMPK. In vitro studies suggested that the glucose transport was increased
considerably by exposing to AICAR of rat muscles cells (Alvim et al., 2015).
The decrease in cold stimulated glucose uptake into brown-adipose tissue (BAT) as well as adipose
tissue AMPK was exhibited at obese and T2D patients. White adipose tissue (WAT) is known as a storage
repository and endocrine organ, in contrast, BAT can preserve thermal homeostasis via the dissipation of
large amount of energy in the heat-form. Many persuasive evidences have showed that AMPK regulated
the BAT development, preservation of mitochondrial activity of BAT and browning of WAT. In addition,
the activation of APMK in muscle and liver increases fatty acid uptake, oxidation and repress lipid and
cholesterol accumulation towards the therapeutic benefit in T2D people (Desjardins & Steinberg, 2018).
T2D treatments with metformin, the sodium glucose cotransporter-2-inhibition (SGT2i) such as canagliflozin drug increase significantly AMPK activation in the liver by restraining mitochondrial function.
Various natural products that decreased hyperglycaemia such as quercetin, berberine and resveratrol also
stimulate AMPK via mitochondrial function (Desjardins & Steinberg, 2018).
164
EBSCOhost - printed on 2/13/2023 11:18 AM via . All use subject to https://www.ebsco.com/terms-of-use
Medicinal Plants for the Treatment of Type 2 Diabetes
Protein tyrosine phosphatase 1B (PTP1B)
The superfamily of protein tyrosine phosphatases (PTPs) and protein tyrosine kinases (PTKs) has a regulatory capacity for insulin and leptin signaling pathways via transfer of phosphate groups from specific
tyrosine (Tyr) residues or addition of phosphate groups to Tyr. Hence, PTPs and PTKs are involved in
T2D by the coordinated action as potential targets (Jänne et al., 2009).
PTP1B is a non-transmembrane protein tyrosine- phosphatase associated with negative modulating
insulin and leptin signaling in the cells. It is capable of the dephosphorylation of the activated insulin
receptor (IR) and the IR substrates after autophosphorylating several tyrosine residues on the intracellular kinase domain of IR-β subunit (Jin et al., 2019). PTP1B and T cell protein-tyrosine phosphatase
(TCPTP) were deleted in the hypothalami of obese mice leading to improve leptin and insulin sensitivity,
suppress feeding and enhance browning to reduce adiposity and increase glucose metabolism (Dodd et
al., 2019). A vivo assay has reported that 5’-AMP (pAMP) was promoted in plasma of obese diabetic
mice and exogenous 5’-AMP induced hyperglyceamia as T2D in wild mice. In addition, these adenine
nucleotides also associate with the activity of PTP1B in type 2 diabetes (Yang et al., 2019).
α- Glucosidase
α-glucosidase, an enzyme at intestinal brush border, is responsible for hydrolysis of disaccharides.
Inhibition of α-glucosidase induces to poor and slow absorption of carbohydrates and lead to blood
glucose reduction after a meal. In addition, this inhibition may also promote the liberation of glucagon
like peptide-1 which may increase to their effects on blood glucose levels (Health, 2017). α-glucosidase
inhibitors (AGIs) were recommended as efficiently first-line agents or in combination with other drugs
for T2D treatment. However, some studies have reported that the use of AGIs induced various unusual
adverse hepatic cases and increase of liver function impairment was exhibited in patients using acarbose
compared to patients without this drug. Moreover, flatulence, diarrhea, abdominal bloating and discomfort are common side effects of this agents (Inzucchi et al., 2015).
α-Amylase
α-amylase is also a member of α- glucosidase family which is necessary for the hydrolysis of α-1,4glycosidic bonds in starch, glycogen, oligo and polysaccharides. There are two types of α- amylase in
human body: salivary enzymes and pancreatic enzymes, both of them participate in the digestion which
produces glucose, maltose and oligo saccharides. These monosaccharides absorbed into the circulation
cause an increase of blood glucose level, which is associated with obesity, type 2 diabetes and other
metabolic diseases (Boehlke et al., 2015). Human α- amylase is encoded on chromosome 1 as member
of a multigene family and the different isozymes are only expressed in the salivary glands as well as
pancreas. The amy 1 gene encodes the former amylase expressed in the salivary, mammary and lacrimal
glands, while the pancreas secrete amylase isozyme encoded by the amy 2 gene (Tundis et al., 2010).
α-amylases have been widely researched as potential targets for the treatment of T2D. α- amylase inhibition does not base on regulation of hormones like insulin and glibenclamide, whose use in the long term
may develop the tolerance of these drugs (Bueno et al., 2019).
EBSCOhost - printed on 2/13/2023 11:18 AM via . All use subject to https://www.ebsco.com/terms-of-use
165
Medicinal Plants for the Treatment of Type 2 Diabetes
Advanced Glycation End Products (AGEs)
Glycation plays an important role in instinctive destruction of cellular and extracellular proteins in living organisms. Advanced glycation end products (AGEs) are proteins and/or lipids becoming glycated
and oxidized after constant connection between reducing sugars (e.g., glucose) or short-chain aldehydes
(e.g., glycoaldehyde) and amino groups and/or high level of oxidative stress. There are three independent
pathways creating AGEs in vivo: the Maillard reaction, the Polyol Pathway and the increase of oxidative
stress causing the synthesis of a-dicarbonyl compounds such as glycolaldehyde, glyceraldehyde, glyoxal,
methylglyoxal and 3-deoxyglucosone. These reactive intermediates can further respond with circulating
proteins via a reversible Schiff base and Amadori products leading to additionally form AGEs like glucosepane associated with the mechanism of diabetic complications (Deluyker et al., 2017). The receptor
for advanced glycation end products (RAGE) belongs to the superfamily of immunoglobulins known as
a multi-ligand transmembrane receptor on several cell types including cardiomyocytes, endothelial cells,
macrophages, lymphocytes and ðbroblasts. High-mobility group protein (B)1, Mac-1, amyloid-β-protein,
phosphatidylserine and S-100 calcium-binding protein along with AGEs are among the most recognized
ligands of RAGE (Sanajou et al., 2018). AGEs-RAGE interaction can generate reactive oxygen species
(ROS) by activating nicotinamide adenine dinucleotide phosphate oxidase. ROS cause the alteration of
the protein structure and function as well as the impairment of excitation–contraction coupling at the
cellular level leading to develop cardiac dysfunction (Hegab et al., 2012). In addition, activation of the
AGE-RAGE axis relates to stimulate intracellular oxidative stress formation and activation of NF-κB
in vascular wall cells, resulting in promotion of atherosclerosis/inflammation-related gene expression
associated with vascular complications in diabetes (Yamagishi et al., 2015). Matsui et al. reported that
a RAGE-aptamer abrogated conceivably several diabetes related to renal impairments such as increase
in macrophage inðltration, surge of proðbrotic cytokines and proinñammatory as well as activation of
AGE-RAGE-oxidative stress axis (Matsui et al., 2017).
Based on above mentioned targets, several antidibetic drugs have been studied and used for T2D
patients such as metformin, sulfonylureas, Glinides, SGLT2i, AGIs However, the treatment with these
drugs in long term may cause a number of side effects including diarrhea, flatulence, weight again, nausea, especially, risk of hypoglycemic and therefore, we review different natural products as an important
alternative source of promising candidates against T2D.
NATURAL PRODUCTS USED FOR THE TREATMENT OF TYPE 2 DIABETES
Salvia Miltiorrhiza Bge.
Salvia miltiorrhiza (Labiatae) known as traditional Chinese medicine has been widely used for the
treatment of cerebrovascular diseases- and coronary artery diseases (Huang et al., 2015). The phytochemicals of S. miltiorrhiza reveal that it may include hydrophilic and lipophilic compounds such as
caffeic acid, isoferulic acid, protocatechuic acid, protocatechuic aldehyde, ferulic acid, rosmarinic acid,
dihydrotanshinone I, przewalskin, cryptotanshinone, tanshinone I, tanshinone IIA, salvianolic acid B and
salvianolic acid A (Zhong et al., 2009). In a vivo study, salvianolic acid B (SalB) has been a beneficial
effects on insulin action, glycogen production and activity of antioxidant enzymes, leading to improve
the symptoms of diabetes mellitus. According to this study, SalB (100 and 200 mg/kg) significantly in-
166
EBSCOhost - printed on 2/13/2023 11:18 AM via . All use subject to https://www.ebsco.com/terms-of-use
Medicinal Plants for the Treatment of Type 2 Diabetes
hibited hyperglycaemia and enhanced sensitivity of insulin. Furthermore, the significant decrease of total
cholesterol, non-esterified fatty acids, hepatic and muscle glycogen as well as the increase of high-density
lipoprotein cholesterol were demonstrated in diabetic mice induced by high-fat diet and streptozotocin
(Huang et al., 2015). Another polyphenolic compound, Salvianolic acid A (SalA) notably reduced fasting
blood glucose, 24-h food and water intake, concurrently enhanced mitochondrial function of hepatic and
skeletal muscle tissues. In addition, SalA caused the activation of AMPK phosphorylation via Ca(2+)/
calmodulin-dependent protein kinase β (CaMKKβ)/AMPK signaling and independent of liver kinase 1
(LKB1)/AMPK pathways (Qiang et al., 2015). In a mouse model with diabetic nephropathy, S. miltior-
rhiza extracts ameliorated high levels of 24-h urinary protein excretion and reduced the kidney levels of
transforming growth factor β1, monocytes/macrophages and the receptor for RAGE (Lee et al., 2011).
Qian et al. (2012) showed that reduction of oxidative stress was induced by a decrease in the production
of malondialdehyde at day 30, simultenously increasing the formation of serum glutathione and activity
of antioxidant enzymes such as superoxide dismutase, paraoxonase and glutathione reductase at day 60
after administration of Salvia miltiorrhiza aqueous extract in T2D patients with chronic heart disorder
(Qian et al., 2012).
Punica granatum
An in vitro study examining a number of phenolic components in the extracts of whole pomegranate
containing seeds, peels, flowers and juice found that they had an ability to decrease carbohydrate digestion enzyme activity. The methanolic flower extract prevented α-amylase and α-glucosidase activity,
while the metabolic peel extract and two active compounds (gallic acid, ellagic acid) displayed selective
α-glucosidase inhibition (Kam et al., 2013). In another in vitro screening assay, the methanolic extract of
P. granatum rind inhibited three metabolism-related enzymes: hyaluronidase, tyrosinase and α-amylase
leading to therapeutic applications in many chronic diseases such as diabetes, hypertension and cancer.
The main active compound identified in this extract was quercetin and its inhibitory activities against
these enzymes was competitive, un-competitive and non-competitive, respectively (Ahmed et al., 2019).
The P. granatum seed oil (PSO) also has several bioactive components utilized into controling insulin
resistance as well as diet-induced obesity. Three dietary fatty acids isolated from PSO included punicic
acid, oleic acid, and linoleic acid, which prevented adipogenesis of human adipose-derived mesenchymal stem cells, improved inflammation, reduced glucose uptake and ATP formation. Furthermore,
the study showed that these fatty acids were found to regulate the mRNA expression of the studied
obesity-associated gene transcripts (Trichur Khabeer et al., 2019). Banihani et al. (2014) investigated
the influence of pomegranate juice (PJ) on fasting serum glucose (FSG) levels and insulin levels in 85
participants with type 2 diabetes. They observed significant decrease of FSG levels, insulin resistance
and increase of β-cell function at 3 hours after oral administration of 1.5 mL of PJ, per kg body weight.
This effect did not relate to the sex of participants and was less potent in elderly patients (Banihani et
al., 2014). These studies suggest that Punica granatum extract may be an effective source for the treatment of type 2 diabetes.
EBSCOhost - printed on 2/13/2023 11:18 AM via . All use subject to https://www.ebsco.com/terms-of-use
167